Cullinan Therapeutics has started an FDA New Drug Application for zipalertinib plus chemotherapy in non-small cell lung cancer. The filing, made with Taiho partners, follows initial Phase 3 REZILIENT3 data and marks a key oncology milestone.
published
Cullinan Therapeutics has started an FDA New Drug Application for zipalertinib plus chemotherapy in non-small cell lung cancer. The filing, made with Taiho partners, follows initial Phase 3 REZILIENT3 data and marks a key oncology milestone.
Latest documented BWB result
$APP market result
Sold the $280 10/9 Calls on $APP for $7.80
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.